ID

34478

Beschreibung

A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01615406

Link

https://clinicaltrials.gov/show/NCT01615406

Stichworte

  1. 17.01.19 17.01.19 -
  2. 22.05.19 22.05.19 -
  3. 23.05.19 23.05.19 - Sarah Riepenhausen
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

17. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostate Cancer NCT01615406

Eligibility Prostate Cancer NCT01615406

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
male aged 21 years or older.
Beschreibung

ID.1

Datentyp

boolean

ability to provide signed informed consent and willingness to comply with protocol requirements.
Beschreibung

ID.2

Datentyp

boolean

past biopsy indicating the presence of adenocarcinoma of the prostate gland.
Beschreibung

ID.3

Datentyp

boolean

participant is deemed to have tissue suspicious of prostate cancer involvement that is amenable to biopsy/resection.
Beschreibung

ID.4

Datentyp

boolean

have had, or will undergo diagnostic ct or mri imaging prior to surgery.
Beschreibung

ID.5

Datentyp

boolean

participants must agree to use an acceptable form of birth control throughout the study period. participants must use condoms for a period of seven days after study drug administration, if engaged in sexual activity.
Beschreibung

ID.6

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
participants for whom participating would significantly delay the scheduled standard of care therapy.
Beschreibung

ID.7

Datentyp

boolean

participants administered a radioisotope within 5 physical half lives prior to study enrollment.
Beschreibung

ID.8

Datentyp

boolean

participants with any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study.
Beschreibung

ID.9

Datentyp

boolean

Ähnliche Modelle

Eligibility Prostate Cancer NCT01615406

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
male aged 21 years or older.
boolean
ID.2
Item
ability to provide signed informed consent and willingness to comply with protocol requirements.
boolean
ID.3
Item
past biopsy indicating the presence of adenocarcinoma of the prostate gland.
boolean
ID.4
Item
participant is deemed to have tissue suspicious of prostate cancer involvement that is amenable to biopsy/resection.
boolean
ID.5
Item
have had, or will undergo diagnostic ct or mri imaging prior to surgery.
boolean
ID.6
Item
participants must agree to use an acceptable form of birth control throughout the study period. participants must use condoms for a period of seven days after study drug administration, if engaged in sexual activity.
boolean
Item Group
C0680251 (UMLS CUI)
ID.7
Item
participants for whom participating would significantly delay the scheduled standard of care therapy.
boolean
ID.8
Item
participants administered a radioisotope within 5 physical half lives prior to study enrollment.
boolean
ID.9
Item
participants with any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study.
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video